Patents Examined by Garnette D. Draper
  • TNF receptors, TNF binding proteins and DNAS coding for them
    Patent number: 6440693
    Abstract: DNA sequences coding for a TNF-binding protein and for the TNF receptor of which this protein constitutes the soluble domain. The DNA sequences can be used for preparing recombinant DNA molecules in order to produce TNF-binding protein and TNF receptor. Recombinant TNF-binding protein is used in pharmaceutical preparations for treating indications in which TNF has a harmful effect. With the aid of the TNF receptor or fragments thereof or with the aid of suitable host organisms transformed with recombinant DNA molecules containing the DNA which codes for the TNF receptor or fragments or modifications thereof, it is possible to investigate substances for their interaction with the TNF receptor and/or for their effect on the biological activity of TNF.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: August 27, 2002
    Inventors: Rudolf Hauptmann, Adolf Himmler, Ingrid Maurer-Fogy, Christian Stratowa
  • OB polypeptides, modified forms and derivatives
    Patent number: 6429290
    Abstract: The present invention relates generally to the control of body weight of animals including mammals and humans, and more particularly to materials identified herein as modulators of body weight, and to diagnostic and therapeutic uses of such modulators. In its broadest aspect, the present invention relates to nucleotide sequences corresponding to the murine and human OB gene, and two isoforms thereof, and proteins expressed by such nucleotides or degenerate variations thereof, that demonstrate the ability to participate in the control of mammalian body weight and that have been postulated to play a critical role in the regulation of body weight and adiposity. The present invention further provides nucleic acid molecules for use as molecular probes or as primers for polymerase chain reaction (PCR) amplification. In further aspects, the present invention provides cloning vectors and mammalian expression vectors comprising the nucleic acid molecules of the invention.
    Type: Grant
    Filed: May 10, 1995
    Date of Patent: August 6, 2002
    Assignee: The Rockefeller University
    Inventors: Jeffrey M. Friedman, Yiying Zhang, Ricardo Proenca
  • Method of ameliorating the harmful effects of TNF using a polypeptide having the ability to bind to TNF
    Patent number: 6417158
    Abstract: DNA sequences coding for a TNF-binding protein and for the TNF receptor of which this protein constitutes the soluble domain. The DNA sequences can be used for preparing recombinant DNA molecules in order to produce TNF-binding protein and TNF receptor. Recombinant TNF-binding protein is used in pharmaceutical preparations for treating indications in which TNF has a harmful effect. With the aid of the TNF receptor or fragments thereof or with the aid of suitable host organisms transformed with recombinant DNA molecules containing the DNA which codes for the TNF receptor or fragments or modifications thereof, it is possible to investigate substances for their interaction with the TNF receptor and/or for their effect on the biological activity of TNF.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: July 9, 2002
    Assignee: Amgen, Inc.
    Inventors: Rudolf Hauptmann, Adolf Himmler, Ingrid Maurer-Fogy, Christian Stratowa
  • TNF Receptors, TNF binding proteins and DNAs coding for them
    Patent number: 6271346
    Abstract: DNA sequences coding for a TNF-binding protein and for the TNF receptor of which this protein constitutes the soluble domain. The DNA sequences can be used for preparing recombinant DNA molecules in order to produce TNF-binding protein and TNF receptor. Recombinant TNF-binding protein is used in pharmaceutical preparations for treating indications in which TNF has a harmful effect. With the aid of the TNF receptor or fragments thereof or with the aid of suitable host organisms transformed with recombinant DNA molecules containing the DNA which codes for the TNF receptor or fragments or modifications thereof, it is possible to investigate substances for their interaction with the TNF receptor and/or for their effect on the biological activity of TNF.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: August 7, 2001
    Assignee: Amgen Inc.
    Inventors: Rudolf Hauptmann, Adolf Himmler, Ingrid Maurer-Fogy, Christian Stratowa
  • IL-13 Receptor chain
    Patent number: 6268480
    Abstract: IL-13 receptor proteins, methods for their production, inhibitors of binding of IL-13 and its receptor and methods for their identification are also disclosed.
    Type: Grant
    Filed: April 30, 1997
    Date of Patent: July 31, 2001
    Assignee: Genetics Institute, Inc.
    Inventors: Mary Collins, Debra Donaldson, Lori Fitz, Tamlyn Neben, Matthew Whitters, Clive Wood
  • Methods of inhibiting binding and treating Ig-mediated responses with IL-13 receptor
    Patent number: 6248714
    Abstract: IL-13 receptor proteins, methods for their production, inhibitors of binding of IL-13 and its receptor methods of mediating-Ig-responses and methods for their identification are also disclosed.
    Type: Grant
    Filed: April 30, 1997
    Date of Patent: June 19, 2001
    Assignee: Genetics Institute, Inc.
    Inventors: Mary Collins, Debra Donaldson, Lori Fitz, Tamlyn Neben, Matthew Whitters, Clive Wood
  • Method for increasing hematopoietic progenitor cells by stem cell factor polypeptides
    Patent number: 6248319
    Abstract: Novel stem cell factors, oligonucleotides encoding the same, and methods of production, are disclosed. Pharmaceutical compositions and methods of treating disorders involving blood cells are also disclosed.
    Type: Grant
    Filed: May 24, 1995
    Date of Patent: June 19, 2001
    Inventors: Krisztina M. Zsebo, Robert A. Bosselman, Sidney V. Suggs, Francis H. Martin
  • Antibody immunoreactive with a human cytokine designated LERK-6
    Patent number: 6232447
    Abstract: The invention is directed to antibodies immunoreactive with a Human LERK-6 as a purified and isolated protein, the DNA encoding the LERK-6, host cells transfected with cDNAs encoding LERK-6.
    Type: Grant
    Filed: October 15, 1998
    Date of Patent: May 15, 2001
    Assignee: Immunex Corporation
    Inventor: Douglas P. Cerretti
  • DNS encoding stem cell factor
    Patent number: 6218148
    Abstract: Novel stem cell factors, oligonucleotides encoding the same, and methods of production, are disclosed. Pharmaceutical compositions and methods of treating disorders involving blood cells are also disclosed.
    Type: Grant
    Filed: December 21, 1993
    Date of Patent: April 17, 2001
    Assignee: Amgen Inc.
    Inventors: Krisztina M. Zsebo, Robert A. Bosselman, Sidney V. Suggs, Francis H. Martin
  • Methods of identifying inhibitors of binding of IL-13 to the IL-13 receptor chain
    Patent number: 6214559
    Abstract: Methods of identifying inhibitors of binding of IL-13 and its receptor and methods for their identification are also disclosed.
    Type: Grant
    Filed: April 30, 1997
    Date of Patent: April 10, 2001
    Assignee: Genetics Institute, Inc.
    Inventors: Mary Collins, Debra Donaldson, Lori Fitz, Tamlyn Neben, Matthew Whitters, Clive Wood
  • Nucleic acids encoding novel orphan cytokine receptors
    Patent number: 6207413
    Abstract: The present invention provides for nucleic acid sequences that encode novel mammalian receptor polypeptides, designated OCR1. The invention also provides assay systems that may be used to detect and/or measure ligands that bind the MAMMALIAN OCR1 gene product. The present invention also provides for diagnostic and therapeutic methods based on the interaction between MAMMALIAN OCR1 and agents that initiate signal transduction through binding to MAMMALIAN OCR1. In a specific embodiment, the MAMMALIAN OCR1 may HUMAN OCR1 or MOUSE OCR1.
    Type: Grant
    Filed: July 22, 1998
    Date of Patent: March 27, 2001
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventor: Piotr J. Masiakowski
  • DNA encoding stem cell factor
    Patent number: 6207417
    Abstract: Novel stem cell factors, oligonucleotides encoding the same, and methods of production, are disclosed. Pharmaceutical compositions and methods of treating disorders involving blood cells are also disclosed.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: March 27, 2001
    Inventors: Krisztina M. Zsebo, Robert A. Bosselman, Sidney V. Suggs, Francis H. Martin
  • Stem cell factor and compositions
    Patent number: 6207802
    Abstract: Novel stem cell factors, oligonucleotides encoding the same, and methods of production, are disclosed. Pharmaceutical compositions and methods of treating disorders involving blood cells are also disclosed.
    Type: Grant
    Filed: November 9, 1994
    Date of Patent: March 27, 2001
    Assignee: Amgen Inc.
    Inventors: Krisztina M. Zsebo, Robert A. Bosselman, Sidney V. Suggs, Francis H. Martin
  • DNA encoding a human tubby homolog
    Patent number: 6204372
    Abstract: The present invention provides a novel human tubby homolog (NHT) and polynucleotides which identify and encode NHT. The invention also provides expression vectors, host cells, agonists, antibodies, or antagonists. The invention also provides methods for treating disorders associated with appetite and eating.
    Type: Grant
    Filed: March 6, 1997
    Date of Patent: March 20, 2001
    Assignee: Incyte Genomics, Inc.
    Inventors: Samuel T. Labrie, Preeti Lal, Lynn E. Murry
  • DNA encoding a cytokine
    Patent number: 6204021
    Abstract: The present invention provides novel human cytokines (designated individually as NHC-1 and NHC-2, and collectively as NHC) and polynucleotides which identify and encode NHC. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding NHC and a method for producing NHC. The invention also provides for use of NHC and agonists, antibodies, or antagonists specifically binding NHC, in the prevention and treatment of diseases associated with expression of NHC. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding NHC for the treatment of diseases associated with the expression of NHC. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding NHC.
    Type: Grant
    Filed: January 31, 1997
    Date of Patent: March 20, 2001
    Assignee: Incyte Genomics, Inc.
    Inventors: Olga Bandman, Phillip R. Hawkins, Lynn E. Murry, Surya K. Goli
  • Stem cell factor
    Patent number: 6204363
    Abstract: Novel stem cell factors, oligonucleotides encoding the same, and methods of production, are disclosed. Pharmaceutical compositions and methods of treating disorders involving blood cells are also disclosed.
    Type: Grant
    Filed: November 25, 1992
    Date of Patent: March 20, 2001
    Assignee: Amgen Inc.
    Inventors: Krisztina M. Zsebo, Robert A. Bosselman, Sidney V. Suggs, Francis H. Martin
  • Assay kits for detection and methods of inhibiting IL-17 binding
    Patent number: 6197525
    Abstract: Isolated receptors for IL-17, DNA's encoding such receptors, pharmaceutical compositions made therefrom, detection assays and methods of inhibiting binding of the receports are disclosed. The isolated receptors can be used to regulate an immune response.
    Type: Grant
    Filed: February 11, 1998
    Date of Patent: March 6, 2001
    Assignee: Immunex Corporation
    Inventors: Zhengbin Yao, Melanie K. Spriggs, William C. Fanslow
  • Cytokine designated lerk-6
    Patent number: 6194172
    Abstract: The invention is directed to LERK-6 as a purified and isolated protein, the DNA encoding the LERK-6, host cells transfected with cDNAs encoding LERK-6.
    Type: Grant
    Filed: October 15, 1998
    Date of Patent: February 27, 2001
    Assignee: Immunex Corporation
    Inventor: Douglas P. Cerretti
  • Methods of treating graft rejection with the IL-17 receptor
    Patent number: 6191104
    Abstract: Isolated receptors for IL-17, DNA's encoding such receptors, pharmaceutical compositions made therefrom, and methods of treatment using the IL-17 receptors are disclosed. The isolated receptors can be used to regulate an immune response.
    Type: Grant
    Filed: February 11, 1998
    Date of Patent: February 20, 2001
    Assignee: Immunex Corporation
    Inventors: Melanie K. Spriggs, William C. Fanslow
  • Tubby 2 polypeptides
    Patent number: 6187908
    Abstract: Tubby 2 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing Tubby 2 polypeptides and polynucleotides in the design of protocols for the treatment of diabetes, obesity, and atherosclerosis, among others, and diagnostic assays for such conditions.
    Type: Grant
    Filed: November 25, 1997
    Date of Patent: February 13, 2001
    Assignee: SmithKline Beecham, P.L.C.
    Inventors: Jonathan Alexander Terrett, Tania Tamson Testa, Israel Simon Gloger, Stephen A. Hughes, Trudy Rachel Doe